US medical giants say Australia’s Pharmaceutical Benefits Scheme is an “egregious and discriminatory” program that Trump should target in the next wave of tariffs.
Disclaimer: The article linked is from a single source with a single perspective. Make sure to cross-check information against multiple sources to get a comprehensive view on the situation.
its per vial to, besides that the slow, delayed and fast release insulin are more expensive too.